Nexavar 200mg Tablet

Most side effects of Nexavar 200mg Tablets do not require medical attention, as they may disappear as your body adjusts to the medicine. In case these side effects become worse, consult your doctor immediately.
Common Side Effects

• Tiredness, weakness, or flu‑like symptoms
• Nausea, vomiting, stomach or abdominal pain, diarrhea
• Loss of appetite and weight loss
• Hair thinning or patchy hair loss
• Rash, skin problems, or dry/itchy skin
• Painful blisters on hands and feet (hand‑foot skin reaction)
• Headache or infection
• Low calcium levels in the blood

Serious Side Effects

• Severe skin reactions (Stevens‑Johnson Syndrome, toxic epidermal necrolysis)
  
• Decreased blood flow to the heart, heart problems
  
• High blood pressure
  
• Increased risk of bleeding (blood in urine, stool, vomit, or cough)
  
• Liver problems
  
• Delayed or impaired wound healing
  

• Nexavar tablets 200 mg are usually administered twice daily or as directed by the physician. Nexavar should be taken intact along with a glass of water on an empty stomach, one hour before or two hours after food.
• In order to maximize the effects of this tablet, it is necessary that you strictly follow the instructions of the doctor and never change the dosage on your own.
• If you find that you are feeling fine even with the intake of the medication, continue with the treatment as per the doctor's instructions.
  

• Nexavar 200 mg acts on different kinases, which are enzymes that promote tumor growth and proliferation.
  
• This Nexavar tablet inhibits RAF kinases, which prevent cell replication, and VEGF receptors, which prevent the formation of blood vessels.
  
• In turn, by depriving the tumor of its nutrient supply, it helps reduce the nourishment of cancer cells.
  
• Furthermore, this medication disrupts the signals that regulate tumor development through inhibition of PDGFR and KIT.
  
• In general, Nexavar is a treatment approach that targets the cancer cells as well as their vessels.
  

• Arora, S. P., Moseley, J. L., Arellano, L. M., Salazar, M., Altermatt, B., Fuentes, L., Pham, V. T., Huang, G., Sun, L., Michalek, J., & Mahalingam, D. (2025, January 27). Phase II study of modulation of sorafenib‑induced autophagy using hydroxychloroquine in advanced hepatocellular cancer (HCC). Journal of Clinical Oncology, 43(4_suppl), 586. https://doi.org/10.1200/JCO.2025.43.4_suppl.586.
  
• Author(s) unspecified. (2023). Real-world effectiveness and tolerability of sorafenib in unresectable hepatocellular carcinoma: A U.S. multicenter retrospective cohort study. OncoDaily.
  
• Author(s) unspecified. (2024). Sorafenib plus hepatic arterial infusion chemotherapy vs sorafenib monotherapy in advanced hepatocellular carcinoma: A systematic review and meta-analysis. Journal of Clinical Medicine.
  
• Bayer HealthCare & Roche. (2024). Phase III randomized study of sorafenib plus erlotinib (SEARCH) versus sorafenib monotherapy in advanced hepatocellular carcinoma. Clinical Trial Protocol.
  
• Fan, G., & Wei, X. (2025). Immune checkpoint inhibitor combinations versus sorafenib as first-line therapy in hepatocellular carcinoma: Systematic review and meta-analysis of clinical trials. Therapeutic Advances in Medical Oncology, 17, 1–14.